The Management of Atopic Dermatitis: Entering a New Paradigm
Jointly provided by
Impact Education, LLC    
This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

You Are Invited to a LIVE Free CME/CNE/CPE Webcast:
The Management of Atopic Dermatitis: Entering a New Paradigm Live Webcast

Live Webcast Dates

Thursday June 28, 2018 12:30 PM - 2:00 PM ET
Tuesday September 11, 2018 1:00 PM - 2:30 PM ET
Wednesday October 3, 2018 12:30 PM - 2:00 PM ET

  • Review of recently approved and emerging therapies
  • Quality standards, health care policy, and benefit designs
  • Care management strategies to boost adherence to treatment plans
  • Current evidence-based diagnosis and treatment data to optimize clinical outcomes
Jeffrey D. Dunn, PharmD, MBA
Vice President
Clinical Strategy and Programs and Industry Relations
MagellanRx Management
Edmund Pezalla, MD, MPH
Enlightenment Bioconsult, LLC
Paul Yamauchi, MD, PhD
Clinical Assistant Professor of Dermatology
David Geffen School of Medicine at UCLA
Adjunct Associate Professor
John Wayne Cancer Institute
  • Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
  • Pharmacy directors, specialty pharmacists, quality directors, care managers, registered nurses, and other managed care and payer organization professionals

Atopic dermatitis (AD), or eczema, is a complex, chronic, relapsing inflammatory skin disease marked by pruritus and skin irritation. Recent studies have documented the adverse effects of AD on mental health and quality of life and new evidence suggests a relationship between AD and other chronic, nonallergic conditions including obesity, cardiovascular disease, autoimmunity, and malignancies. The webcasts are focused on AD diagnosis and treatment, impact of emerging therapies, adherence to therapy, and management of the pharmacy benefit. Each is specifically designed to meet the needs of health care decision makers (HCDMs) from health plans, insurers, health systems, and other payers responsible for the benefit management, therapeutic category review, and AD clinical pathway development.


After completing the activity, participants should be better able to:
  • Review recent insights into the pathophysiology of AD
  • Discuss the safety, efficacy and attributes of emerging therapies for the treatment of AD
  • Evaluate strategies to align diagnosis and treatment strategies with current evidence-based guidelines
  • Apply practical approaches to improve adherence to AD treatment
  • Assess benefit design strategies to improve overall patient outcomes for AD
Opening Comments/Overview
Jeffrey D. Dunn, PharmD, MBA
Clinical Update: The Impact of Novel Therapies
Paul Yamauchi, MD, PhD
Care Management Strategies to Improve Clinical and Economic Outcomes
Edmund Pezalla, MD, MPH
Benefit Design and Specialty Pharmacy Services for Optimal Management
Jeffrey D. Dunn, PharmD, MBA
Audience Question and Answer Session

Key Takeaways and Closing Comments
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008162-9999-18-082-L01-P
Type of Activity: Application

For Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to the CPE Monitor as required. After receipt of a completed activity evaluation form, you will be provided with instructions to have your credit immediately uploaded to the CPE Monitor.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

If you have any questions, please call (215) 619-8812 or email